Skip to main content

Advertisement

SpringerLink
Log in

Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Target-specific oral anticoagulants (TSOACs) dabigatran, rivaroxaban and apixaban are approved for the prevention and treatment of thromboembolism in several clinical settings. Bleeding is the major complication of anticoagulant therapy, including TSOACs, and anticoagulant reversal strategies are highly desired for the management of anticoagulant-associated major bleeding in addition to maximum supportive care and procedural/surgical intervention. Unlike VKAs for which vitamin K and coagulation factor replacement with prothrombin complex concentrate (PCC) can restore hemostasis, there are no clinically available agents proven to reverse TSOAC anticoagulant effect and ameliorate TSOAC-related major bleeding. This narrative review critically evaluates the evidence for TSOAC reversal using non-specific reversal agents PCC, activated PCC (APCC) and recombinant activated factor VII (rVIIa) which have been assessed primarily using in vitro experiments, animal models and healthy human volunteers. Aripazine is a novel agent undergoing clinical development for non-specific anticoagulant reversal, including TSOACs. Data are presented regarding specific reversal agents idarucizumab (dabigatran) and andexanet alfa (oral factor Xa inhibitors) currently being evaluated in clinical trials. A practical approach to management of patients with TSOAC-associated bleeding is also provided. There is an urgent need for clinical studies that evaluate the efficacy and safety of reversal strategies for TSOAC-related major bleeding with assessment of clinical outcomes such as bleeding and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Providencia R, Grove EL, Husted S, Barra S, Boveda S, Morais J (2014) A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res 134(6):1253–1264

    Article  CAS  Google Scholar 

  2. Castellucci LA, Cameron C, Le Gal G et al (2014) Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 312(11):1122–1135

    Article  CAS  PubMed  Google Scholar 

  3. Larsen TB, Rasmussen LH, Skjoth F et al (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61(22):2264–2273

    Article  CAS  PubMed  Google Scholar 

  4. Graham DJ, Reichman ME, Wernecke M et al (2014) Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. doi:10.1161/CIRCULATIONAHA.114.012061

  5. Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64(11):1128–1139

    Article  CAS  PubMed  Google Scholar 

  6. Dentali F, Marchesi C, Pierfranceschi MG et al (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106(3):429–438

    Article  CAS  PubMed  Google Scholar 

  7. Ehrlich HJ, Henzl MJ, Gomperts ED (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8(2):83–90

    Article  CAS  PubMed  Google Scholar 

  8. Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2(10):1700–1708

    Article  CAS  PubMed  Google Scholar 

  9. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14):1573–1579

    Article  CAS  PubMed  Google Scholar 

  10. Levi M, Moore KT, Castillejos CF et al (2014) Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 12(9):1428–1436

    Article  CAS  PubMed  Google Scholar 

  11. Zahir H, Brown KS, Vandell A et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131(1):82–90

  12. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T (2012) Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107(2):253–259

    Article  CAS  PubMed  Google Scholar 

  13. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R (2014) Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 111(5):989–995

    Article  CAS  PubMed  Google Scholar 

  14. Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23(2):138–143

    Article  CAS  PubMed  Google Scholar 

  15. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A (2013) In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban. J Thromb Haemost 11(6):1111–1118

    Article  CAS  PubMed  Google Scholar 

  16. Korber MK, Langer E, Ziemer S, Perzborn E, Gericke C, Heymann C (2014) Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study. Clin Appl Thromb Hemost 20(7):735–740

    Article  PubMed  Google Scholar 

  17. Perzborn E, Heitmeier S, Laux V, Buchmuller A (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 133(4):671–681

    Article  CAS  PubMed  Google Scholar 

  18. van Ryn J, Schurer J, Kink-Eiband M, Clemens A (2014) Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 120(6):1429–1440

    Article  PubMed  Google Scholar 

  19. Solbeck S, Meyer MA, Johansson PI et al (2014) Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography. Int J Cardiol 176(3):794–799

    Article  PubMed  Google Scholar 

  20. Key NS, Negrier C (2007) Coagulation factor concentrates: past, present, and future. Lancet 370(9585):439–448

    Article  CAS  PubMed  Google Scholar 

  21. Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I et al (2014) Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates. Circ J [Epub ahead of print]

  22. Chan HHW, Atkinson HM, Goncharenko M, Berry LR, Chan AKC (2011) Reversal of dabigatran using recombinant activated factor VII and activated prothrombin complex concentrates in thromboelastography assay. J Thromb Haemost 9(Suppl 2):576–577

    Google Scholar 

  23. Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S (2013) The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 35(2):222–224

    Article  PubMed  Google Scholar 

  24. Halim AB, Samama MM, Mendell J (2014) Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 134(4):909–913

    Article  CAS  PubMed  Google Scholar 

  25. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108(2):217–224

    Article  CAS  PubMed  Google Scholar 

  26. Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371(22):2141–2142

    Article  PubMed  Google Scholar 

  27. Hollenbach S, Lu G, DeGuzman F et al (2014) Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model-only andexanet reverses markers of fXa-mediated anticoagulation. Circulation 130(Suppl 2):A14657

    Google Scholar 

  28. Lu G, Kotha J, Cardenas JM et al (2014) Abstract 18218: in vitro characterization of andexanet alfa (PRT064445), a specific fxa inhibitor antidote versus aripazine (PER977), a non-specific reversal agent. Circulation 130(Suppl 2):A18218

  29. van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J (2012) In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran [abstract]. Blood 120(21):Abstract 3418

  30. Van Ryn J, Litzenburger T, Waterman A et al (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models [abstract]. J Am Coll Cardiol 57(14):E1130

    Article  Google Scholar 

  31. Grottke O, Honickel M, van Ryn J, ten Cate H, Spronk H, Rossaint R (2014) Abstract 18544: bloods loss in dabigatran anticoagulated pigs with polytrauma is significantly reduced by early therapy with activated and non-activated prothrombin complex concentrates. Circulation 130(Suppl 2):A18544

    Google Scholar 

  32. Toth J, Gan G, van Ryn J et al (2012) Reversal of dabigatran’s anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling. Blood 120(21):Abstract 22

  33. Glund S, Stangier J, Schmohl M et al (2013) Abstract 17765: a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 128(22 Supplement):A17765

    Google Scholar 

  34. Glund S, Stangier J, Schmohl M et al (2014) Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 124(21):344

    Google Scholar 

  35. Lu G, DeGuzman FR, Hollenbach SJ et al (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19(4):446–451

    Article  CAS  PubMed  Google Scholar 

  36. Crowther M, Levy GG, Lu G et al (2014) A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 124(21):4269

    Google Scholar 

  37. Crowther M, Kitt M, Lorenz T et al (2013) A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. J Thromb Haemost 11(Suppl 2):30

    Google Scholar 

  38. Crowther M, Levy GG, Lu G et al (2014) ANNEXA-A: A phase 3 randomized, double-blind, placebo-controlled trial demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Circulation 130(23):2105–2126

    Article  Google Scholar 

  39. van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127

    Article  PubMed  Google Scholar 

  40. Stangier J, Rathgen K, Stahle H, Mazur D (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259–268

    Article  CAS  PubMed  Google Scholar 

  41. Khadzhynov D, Wagner F, Formella S et al (2013) Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 109(4):596–605

    Article  CAS  PubMed  Google Scholar 

  42. Crescenzi G, Landoni G, Biondi-Zoccai G et al (2008) Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 109(6):1063–1076

    Article  CAS  PubMed  Google Scholar 

  43. Henry DA, Carless PA, Moxey AJ et al (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (3):CD001886. doi:10.1002/14651858.CD001886.pub4

  44. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield W (2012) Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but not dabigatran etexilate. Transfusion 52:56A–57A

    Article  Google Scholar 

  45. Zhou W, Schwarting S, Illanes S et al (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42(12):3594–3599

    Article  PubMed  Google Scholar 

  46. Pragst I, Zeitler SH, Doerr B et al (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 10(9):1841–1848

    Article  CAS  PubMed  Google Scholar 

  47. Siegal DM, Cuker A (2014) Reversal of target-specific oral anticoagulants. Drug Discov Today 19(9):1465–1470

    Article  CAS  PubMed  Google Scholar 

  48. Godier A, Miclot A, Le Bonniec B et al (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116(1):94–102

    Article  CAS  PubMed  Google Scholar 

  49. Perzborn E, Gruber A, Tinel H et al (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 110(1):162–172

    Article  CAS  PubMed  Google Scholar 

  50. Martin AC, Le Bonniec B, Fischer AM et al (2013) Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 168(4):4228–4233

    Article  PubMed  Google Scholar 

  51. Siegal DM, Cuker A (2013) Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 35(3):391–398

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

Deborah M. Siegal has participated in an advisory board for Boehringer Ingelheim.

Author information

Authors and Affiliations

  1. Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Canada

    Deborah M. Siegal

Authors
  1. Deborah M. Siegal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah M. Siegal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siegal, D.M. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39, 395–402 (2015). https://doi.org/10.1007/s11239-015-1167-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1167-9

Keywords

Search

Navigation